Cruz, Alvaro A; Riley, John H; Bansal, Aruna T; Ponte, Eduardo V; Souza-Machado, Adelmir; Almeida, Paula C A; Biao-Lima, Valmar; Davis, Maggie; Bates, Stewart; Adcock, Ian M; Sterk, Peter J; Chung, Kian Fan (2020). Asthma similarities across ProAR (Brazil) and U-BIOPRED (Europe) adult cohorts of contrasting locations, ethnicity and socioeconomic status. Respiratory medicine, 161, p. 105817. Elsevier 10.1016/j.rmed.2019.105817
Text
asthma similarities across ProAR and U-BIOPRED_2019.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (851kB) |
BACKGROUND
Asthma prevalence is 339 million globally. 'Severe asthma' (SA) comprises subjects with uncontrolled asthma despite proper management.
OBJECTIVES
To compare asthma from diverse ethnicities and environments.
METHODS
A cross-sectional analysis of two adult cohorts, a Brazilian (ProAR) and a European (U-BIOPRED). U-BIOPRED comprised of 311 non-smoking with Severe Asthma (SAn), 110 smokers or ex-smokers with SA (SAs) and 88 mild to moderate asthmatics (MMA) while ProAR included 544 SA and 452 MMA. Although these projects were independent, there were similarities in objectives and methodology, with ProAR adopting operating procedures of U-BIOPRED.
RESULTS
Among SA subjects, age, weight, proportion of former smokers and FEV1 pre-bronchodilator were similar. The proportion of SA with a positive skin prick tests (SPT) to aeroallergens, the scores of sino-nasal symptoms and quality of life were comparable. In addition, blood eosinophil counts (EOS) and the % of subjects with EOS > 300 cells/μl were not different. The Europeans with SA however, were more severe with a greater proportion of continuous oral corticosteroids (OCS), worse symptoms and more frequent exacerbations. FEV1/FVC pre- and post-bronchodilator were lower among the Europeans. The MMA cohorts were less comparable in control and treatment, but similar in the proportion of allergic rhinitis, gastroesophageal reflux disease and EOS >3%.
CONCLUSIONS
ProAR and U-BIOPRED cohorts, with varying severity, ethnicity and environment have similarities, which provide the basis for global external validation of asthma phenotypes. This should stimulate collaboration between asthma consortia with the aim of understanding SA, which will lead to better management.